Loperamid "Bluefish" 2 mg tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

loperamid "bluefish" 2 mg tabletter

bluefish pharmaceuticals ab - loperamidhydrochlorid - tabletter - 2 mg

Loperamid "Mashal" 2 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

loperamid "mashal" 2 mg filmovertrukne tabletter

mashal healthcare a/s - loperamidhydrochlorid - filmovertrukne tabletter - 2 mg

Lacosamide UCB Den Europæiske Union - dansk - EMA (European Medicines Agency)

lacosamide ucb

ucb pharma s.a. - lacosamid - epilepsier, delvis - antiepileptika, - lacosamide ucb er angivet som monoterapi og tillægsbehandling terapi i behandlingen af delvis-anfald med eller uden sekundær generalisering hos voksne, unge og børn fra 4 år med epilepsi.

Lacosamide Accord Den Europæiske Union - dansk - EMA (European Medicines Agency)

lacosamide accord

accord healthcare s.l.u. - lacosamid - epilepsi - antiepileptika, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Lacosamide Adroiq Den Europæiske Union - dansk - EMA (European Medicines Agency)

lacosamide adroiq

extrovis eu ltd. - lacosamid - epilepsi - antiepileptika, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.